P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis

P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after percutaneous coronary intervention (PCI) in the modern era. Clinical trials have shown that it could lower the risk of bleeding complications without increased ischemic events as compared to standard dual antiplatelet...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Wen-Han Feng, Yong-Chieh Chang, Yi-Hsiung Lin, Hsiao-Ling Chen, Chun-Yin Chen, Tsung-Han Lin, Tzu-Chieh Lin, Ching-Tang Chang, Hsuan-Fu Kuo, Hsiu-Mei Chang, Chih-Sheng Chu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2023-02-01
coleção:	Pharmaceuticals
Assuntos:	P2Y12 inhibitor monotherapy percutaneous coronary intervention (PCI) acute coronary syndrome (ACS)
Acesso em linha:	https://www.mdpi.com/1424-8247/16/2/232
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!